NextCure (FRA:2US) Other Long-Term Liabilities : €0.69 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is NextCure Other Long-Term Liabilities?

NextCure's other long-term liabilities for the quarter that ended in Mar. 2024 was €0.69 Mil.

NextCure's quarterly other long-term liabilities declined from Sep. 2023 (€0.76 Mil) to Dec. 2023 (€0.72 Mil) and declined from Dec. 2023 (€0.72 Mil) to Mar. 2024 (€0.69 Mil).

NextCure's annual other long-term liabilities increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.85 Mil) but then declined from Dec. 2022 (€0.85 Mil) to Dec. 2023 (€0.72 Mil).

NextCure Other Long-Term Liabilities Historical Data

The historical data trend for NextCure's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCure Other Long-Term Liabilities Chart

NextCure Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

NextCure Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

NextCure Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

NextCure Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of NextCure's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCure (FRA:2US) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (FRA:2US) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

NXTC:USA

Address

9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705

Website

https://www.nextcure.com

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include NC410 a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1, NC762 a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or B7-H4, a protein expressed on multiple tumor types, and NC525 (LAIR-1 mAb) is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or AML, blast cells, and leukemic stem cells, or LSCs.

NextCure (FRA:2US) Headlines

No Headlines